The BioHub - The Avetix Podcast - S2 Ep71 - Nick Manusos - CEO of Kenai Therapeutics Welcome back to another episode of The BioHub, we were delighted to welcome on Nick Manusos, the CEO of Kenai Therapeutics, a pioneering biotech company developing neuron replacement therapies for neurological disorders. Nick’s journey spans decades of innovation and leadership—from senior roles at global pharma giants like Baxter, Takeda, and Abbott, to founding and leading cutting-edge startups like Iota Biosciences and Opsis Therapeutics. Under his guidance, Kenai Therapeutics has secured groundbreaking funding and is advancing life-changing therapies for patients with Parkinson’s disease. He holds an MBA from Northwestern University’s Kellogg School of Management and a BBA from the University of Wisconsin, bringing a rare combination of business acumen and scientific vision to the table. Nick joins us today to share his insights on pioneering stem cell therapies, building biotech startups from the ground up, and what it takes to turn cutting-edge science into real-world solutions.

Kenai Therapeutics is on a mission to cure neurological conditions like #Parkinsons using #celltherapies. Nick Manusos, CEO of Kenai, joined The Bio Hub to share his path to Kenai, and the lessons he learned along the way. #SaiseiPortCo @kenaitx.bsky.social

Listen here: bit.ly/42aLMSY

At #Expo2025Osaka - a global event dedicated to “Designing Future Society for Our Lives” - #SaiseiPortCo United Immunity’s breakthrough platform was named UCB Pharma’s “Most Innovative Technology with Potential for Disruption.” Congrats to President Masato Kishida & team on this incredible honor!

Congratulations to the #Craif team on their Series C financing! Craif is a molecular diagnostic company focused on #EarlyCancerDetection by analyzing a patient's microRNA.

Learn more: craif.com/en/20250428-...
#SaiseiPortCo